NL-OMON52657
Recruiting
Not Applicable
Adoptive therapy with TCR gene-engineered T cells to treat patients with MAGE-C2-positive melanoma and head and neck cancer. - MAGE-C2 TCR T cell therapy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- head and neck squamous cell carcinoma
- Sponsor
- Erasmus MC, Universitair Medisch Centrum Rotterdam
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients must be \>\= 18 years of age.
- •Patients must have:
- •\- inoperable stage IIIc or stage IV cutaneous melanoma, including ocular or
- •mucosal melanoma, progressing after standard of care therapy, or
- •recurrent/metastatic HNSCC
- •Patients must be HLA\-A2 positive.
- •The primary tumor and/or metastasis have to be positive for MAGE\-C2
- •Patients must have a clinical performance status of ECOG 0 or 1\.
- •Patients of both genders must be willing to practice a highly effective method
- •of birth control during treatment and for four months after receiving the
Exclusion Criteria
- •Life expectancy of less than three months.
- •Requirement for systemic steroid therapy.
- •Patients who have active/symptomatic CNS metastases.
- •Patients with pleural effusion or ascites.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 1/2
MAGE-C2 TCR T cell therapy2024-516922-70-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)20
Not yet recruiting
Not Applicable
Adoptive Transfer of T cell Receptor-engineered T cells to treat hepAtocellular Carcinoma recurrence after liver Transplantation: a preclinical feasibility studyLiver CancerPrimary Liver Cell Carcinoma100196541000381610019815NL-OMON47991Erasmus MC, Universitair Medisch Centrum Rotterdam35
Recruiting
Not Applicable
Donor leukapheresis for T-cell receptor gene therapy for treatment of metastatic melanoma (skin cancer)melanomaSkin cancer10040900NL-OMON34342ederlands Kanker Instituut2
Completed
Phase 1
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated CancersVaginal CancerCervical CancerAnal CancerPenile CancerOropharyngeal CancerNCT02280811National Cancer Institute (NCI)12
Recruiting
Not Applicable
Adoptive T cell therapy plus vaccination in metastatic melanoma patientsNL-OMON37167eids Universitair Medisch Centrum25